CKLF like MARVEL transmembrane domain containing 8Genealiases: CKLFSF8 · CKLFSF8-V2
Q-omics provides the consensus-scored CMTM8 profile across patient tissues and cancer cell-line models. CMTM8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CMTM8 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CMTM8 RNA expression shows 18,375 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where CMTM8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CMTM8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CMTM8 survival associations across molecular data types. CMTM8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CMTM8 RNA expression–survival associations across cancer types. High CMTM8 expression shows unfavorable associations in KIRP, UVM, ESCA and SCLC, but favorable associations in KIRC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CMTM8 RNA expression.
This table summarizes CMTM8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CMTM8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CMTM8 shows lower tumor expression in LUSC and higher tumor expression in COAD, BLCA, THCA, STAD and UCEC. The COAD box plot shows higher CMTM8 RNA expression in tumor versus normal tissue (log2 FC = +1.642, t-test p < 0.001).
This table shows molecular features associated with CMTM8 in patient tissues and cancer cell lines. In patient samples, CMTM8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CMTM8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
